Trials / Recruiting
RecruitingNCT05345327
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 994 (estimated)
- Sponsor
- The George Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the trial is to evaluate the effects of the SGLT2 inhibitor, dapagliflozin, compared to metformin on annual decline in eGFR when used as first line therapy in people with Type 2 Diabetes.
Detailed description
This study is a randomised, double blinded clinical trial and will be undertaken in primary care and community sites across Australia and tertiary care centres in Sri Lanka. Following a 4-week active run-in period, eligible participants will be randomised to either dapagliflozin 10mg daily, or metformin XR 2000mg daily in a 1:1 ratio.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | SGLT2 inhibitor |
| DRUG | Metformin | Metformin |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2022-04-25
- Last updated
- 2024-12-20
Locations
8 sites across 2 countries: Australia, Sri Lanka
Source: ClinicalTrials.gov record NCT05345327. Inclusion in this directory is not an endorsement.